Table 1 Characteristics of the enrolled AML patients.
Patient ID | Age | Sex | Diagnosis | Karyotype | Clinical treatment (mg/m2/day) | HLA subtype | Blast counts (%) | |
|---|---|---|---|---|---|---|---|---|
Diagnosis | Post-treatment | |||||||
Patient #1 | 29 | M | AML-M2 | Normal | DAC 20 mg/d d1-5 × 4 courses | HLA-A2+ | 94.5% | 73.7% |
Patient #2 | 31 | F | AML-M2 | Normal | DAC 20 mg/d d1-5 × 4 courses | HLA-A2+ | 62.5% | 4.5% |
Patient #3 | 68 | F | AML-M2 | Normal | DCAG | HLA-A2- | 64% | 39.2% |
Patient #4 | 60 | F | AML-M5 | Normal | DCAG + Chidamide 20 mg/d d1-5 × 4 | HLA-A2- | 73% | 16.3% |
